NCT05084157

Brief Summary

Takotsubo syndrome (TTS) is characterized by severe left ventricular (LV) dysfunction that gradually recovers, thus leading to the commonly accepted belief that it is a transient and self-limiting condition. Histologically, TTS can be accompanied by severe morphological alterations potentially resulting from catecholamine excess followed by microcirculatory dysfunction and direct cardiotoxicity. The affected myocardium, however, has a high potential of structural reconstitution which correlates with the rapid functional recovery. The lack of persistent morphological changes in TTS has been confirmed by original CMR studies which pointed out that the acute phase of the disease is characterized only by remarkable myocardial edema with no evidence of significant late gadolinium enhancement. Indeed, the absence of LGE in TTS patients has become a common diagnostic criterion in most CMR centers. Although some studies have challenged this notion by reporting delayed hyper-enhancement in TTS patients, the intensity and extent of LGE in the acute phase of TTS are less than usually reported in studies of myocardial infarction. The long-term clinical and functional consequences of an acute episode of TTS are still unclear. A recent spectroscopic investigation has shown that long-term (\>1 year) abnormalities in cardiac energetic persist after an acute episode of TTS. Also, a few patients with residual wall motion abnormality in whom LGE fails to resolve (suggesting the acute event resulted in frank infarction) have been reported. However, how often persistent morphologic abnormalities are present after the index episode remains undefined. The possibility exists that fibrosis was undetected at follow-up CMR studies using conventional LGE threshold methods due to the fact that myocardial injury is subtler and there are no confidently recognizable reference regions of normal myocardium. Newer echocardiographic tools (i.e. tissue Doppler) have now the potential to detect persistence of post-TTS LV function abnormalities.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 5, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

October 19, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

February 1, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2023

Completed
Last Updated

January 25, 2022

Status Verified

January 1, 2022

Enrollment Period

9 months

First QC Date

October 5, 2021

Last Update Submit

January 9, 2022

Conditions

Keywords

syndrome

Outcome Measures

Primary Outcomes (1)

  • Left ventricular systolic dysfunction

    The time to the echocardiographic finding of left ventricular systolic dysfunction

    Up to 5 years

Interventions

EchocardiographyDIAGNOSTIC_TEST

Patients will undergo Doppler echocardiography

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed as having Takotsubo Syndrome on the basis of Mayo Criteria

You may qualify if:

  • Diagnosis of TTS according to current International consensus criteria
  • Written informed consent
  • Age 18 years and over

You may not qualify if:

  • Secondary form of TTS (e.g. as it can occur after sepsis, neurological disorders, pheochromocytoma)
  • Durg-induced form of TTS (e.g. after administration of drugs such as dopamine, dobutamine, epinephrine, or norepinephrine)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Takotsubo CardiomyopathySyndrome

Interventions

Echocardiography

Condition Hierarchy (Ancestors)

CardiomyopathiesHeart DiseasesCardiovascular DiseasesVentricular Dysfunction, LeftVentricular DysfunctionDiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cardiac Imaging TechniquesDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisUltrasonographyHeart Function TestsDiagnostic Techniques, Cardiovascular

Study Officials

  • Carlo Gaudio, MD

    University Sapienza

    STUDY CHAIR

Central Study Contacts

Francesco Pelliccia, MD

CONTACT

Giuseppe Marazzi, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 5, 2021

First Posted

October 19, 2021

Study Start

February 1, 2022

Primary Completion

October 30, 2022

Study Completion

October 30, 2023

Last Updated

January 25, 2022

Record last verified: 2022-01